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Abstract 
Background: Hyponatremia is the most common electrolyte disturbance in hospitalized patients, and it represents a 
well-established risk factor for ICU/hospital mortality. The majority of hyponatremic states are associated with ele-
vated arginine vasopressin levels and a preserved sodium pool. Conventional treatment is either not pathophysiologi-
cally oriented or of limited effectiveness. The aim of the present study is to investigate the use of enteral Tolvaptan in 
critically ill hyponatremic patients.
Methods: This is a retrospective observational study in a general ICU. Patients with preserved sodium pool hypona-
tremia refractory to conventional therapy were enrolled. The hemodynamic, renal, and hepatic functions, together 
with sodium and water balance as close as possible to the drug administration and up to 72 h thereafter, were ana-
lyzed. The main outcome was a serum sodium increase of ≥ 4 mmol/L in 24 h; secondary endpoints were the ability 
to maintain serum sodium at 24 and 72 h, a decrease in urine sodium concentration and an increase in sodium-free 
diuresis.
Results: 38 patients were enrolled. The average dose of enteral Tolvaptan was 7.5 mg. 31 patients (81.6 %) increased 
their serum sodium >4 mmol/l/24 h; the average increase was 6.7 ± 3.4 mmol/l during the first 24 h (p < 0.001 vs 
baseline), and this was sustained at 72 h. No adverse effects were reported. Plasma sodium (R = −0.622, p < 0.001), 
urine sodium (R = −0.345, p < 0.001), central venous oxygen saturation (R = 0.401, p = 0.013), and BUN (R = −0.416, 
p = 0.031) before Tolvaptan were all significantly correlated with the absolute increase in serum sodium after the 
administration.
Conclusions: Enteral administration of Tolvaptan seems effective in the treatment of hyponatremia with preserved 
sodium pool in critically ill patients. Even if the study was underpowered to detect significant side effects or complica-
tions of unwarranted fast corrections of hyponatremia, we report no complications.
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Background
In a large-scale epidemiologic study, hyponatremia 
(serum sodium concentration–[Na+]  ≤  135  mmol/L) 
was present at admission in 14.5 % of patients, and dur-
ing hospitalization in an additional 5  % [1]. The risk of 
mortality in those patients is evident even in mild cases 
([Na+] 130–134  mEq/L), which constitute the majority 
of cases of hyponatremia, and the increased risk of death 
persists up to 5 years beyond discharge [1].
In the ICU, the prevalence of hyponatremia on admis-
sion is around 15–20 % [2, 3]; moreover, among patients 
with normal [Na+] at admission, a first episode of ICU-
acquired hyponatraemia develops in 11  % of cases [4]. 
Independent of the severity of the underlying disease, 
both hyponatremia at admission and ICU-acquired 
Open Access
*Correspondence:  michele.umbrello@fastwebnet.it 
1 Unità Operativa di Anestesia e Rianimazione, Azienda Ospedaliera San 
Paolo-Polo Universitario, Via A. Di Rudinì, 8, 20142 Milan, Italy
Full list of author information is available at the end of the article
Page 2 of 9Umbrello et al. Ann. Intensive Care  (2016) 6:1 
hyponatremia are significantly related to ICU and hos-
pital mortality. Similar associations with mortality result 
from the duration of sodium disturbances [3, 4]. Cor-
rection of acute and severe hyponatremia is lifesaving; 
however, despite the widespread clinical impression that 
correction of less severe hyponatremia is also worth-
while, evidence-based data demonstrating clinical benefit 
are limited [5].
[Na+] represents the ratio of total body sodium pool 
to total body water pool [6]. Depending on total body 
sodium stores, hyponatremia can be hypovolemic, nor-
movolemic, or hypervolemic, with body sodium pool 
reduced, preserved, or increased, respectively. However, 
the majority of hyponatremic states in critical illness are 
frequently non-hypovolemic (e.g., syndrome of inap-
propriate antidiuresis–SIAD) [2] and likely associated to 
elevated plasma levels of arginine vasopressin (AVP) [7], 
due to an underlying cause of inappropriate antidiuresis 
[8]. AVP-induced water retention leads to increased body 
water pool and subsequent dilution of serum sodium [9, 
10], with excess total body water relative to the preserved 
total body sodium pool [11].
The traditional approach to the treatment of such 
cases involves restriction of free water intake [12], use of 
loop diuretics [13], demeclocycline [14], osmotic diuret-
ics, such as urea [15] or intravenous administration of 
normal or hypertonic saline [16]. In ICU patients, fluid 
restriction is in fact poorly tolerated and difficult to 
achieve [17], and increased intake of salt does not address 
the causative factor, which is free water excess.
Indeed, loop diuretics result in the excretion of urine 
with a lower sodium concentration than plasma (i.e., 
more water than sodium is excreted, as compared to 
plasma) [13]. The subsequent correction of hyponatremia 
would then occur at the expense of salt depletion. For 
this reason, it is generally recommended that a concomi-
tant administration of both NaCl (as hypertonic saline) 
and furosemide is performed in hyponatremia with nor-
mal sodium pool [18]. In particular, this is the only effec-
tive approach in severe cases of hyponatremia (i.e., coma 
and or convulsions), because the effects of combined salt 
and furosemide are extremely rapid [11]. However, other 
complications besides the reduction in body sodium pool 
can be determined by loop diuretic administration, such 
as hypokalemia, hypochloremia, hypomagnesemia, met-
abolic alkalosis [19], and this explains why this treatment 
is generally reserved to the acute phases of correction 
only [20].
Urea is an osmotic diuretic, and it increases free water 
excretion according to each patient urine osmolality and 
the amount of drug administered. Despite recent positive 
report on its use in critically ill patients [21], clinical data 
with this drug are, however, limited; in addition, urea is 
not a receptor-targeted agent and it has been associated 
with potential side effects (azotemia, nausea/vomiting, 
allergic reactions, renal toxicity, hypernatremia, and/or 
hypokalemia) [21].
Vaptans are a recently introduced class of vasopressin 
V2-receptor antagonists, yielding to an increased elec-
trolyte-free water excretion and, thus, increased serum 
sodium concentration [22]. Several studies showed their 
safety and effectiveness in hyponatremia with preserved 
total body sodium pool in different categories of patients 
[17, 23–27]; however, the experience with these drugs is 
limited in the critical care setting. After positive initial 
experience with oral Tolvaptan in single cases [28, 29], we 
sought to analyze our case series to investigate the short-
term outcomes on water and electrolyte balance for 
patients prescribed oral vaptans for hyponatremia with 
preserved total body sodium pool within our ICU.
Methods
Ethics, consent, and permission
The case series was conducted in a in a 6-bed general 
ICU of a University hospital. After obtaining approval 
from the Institutional Review Board (“Comitato Etico 
Interaziendale Milano Area A”—n. 16413), we enrolled 
patients treated with oral Tolvaptan between the date the 
drug was introduced into our clinical practice, January 
2012, and January 2014. In all cases, decision to admin-
ister Tolvaptan was made by the physician in charge of 
the patient. Patients provided informed consent for 
the utilization of their data. All patient data have been 
anonymized.
Data collection and inclusion criteria
We performed a retrospective analysis of prospec-
tively collected case series; patients were treated fol-
lowing a specific internal protocol for the management 
of hyponatremia, resulting in a heterogeneous popula-
tion of critically ill patients in whom hyponatremia was 
treated homogeneously. The following inclusion cri-
teria were used: (1) diagnosis of clinically significant 
hypoosmolar hyponatraemia ([Na+] ≤  135  mmol/L and 
serum osmolality  <280  mOsm/kg) with raised urine 
osmolality (urine osmolality  >100  mOsm/kg and urine 
sodium  >20  mmol/L) [30]; (2) no history of reduction 
in body sodium pool (i.e., diuretic use, gastrointestinal 
losses, hemorrhage, low sodium intake); (3) lack of clear 
signs of hypovolemia (i.e., tachycardia, pale, cold, and 
clammy skin, delayed capillary refill, hypotension, oligu-
ria, hyperlactatemia, reduced central venous blood oxy-
gen saturation); (4) the presence of a possible underlying 
cause of inappropriate antidiuresis (i.e., central nerv-
ous system disorder, pulmonary diseases, mechanical 
ventilation, drug-induced) [8]; and (5) failure to correct 
Page 3 of 9Umbrello et al. Ann. Intensive Care  (2016) 6:1 
hyponatraemia (absolute increase in [Na+] ≥  4 mmol/L 
over baseline) despite at least 24 h of free water restric-
tion (<1 l); (6) age >18.
Given the limited experience with the drug in this class 
of patients and to avoid the risks of overcorrection, fluid 
restriction was only prescribed before the administration 
of Tolvaptan. As in case of serum sodium overcorrection, 
any saline infusion was temporarily withheld, and further 
correction from urinary free water losses was prevented 
by replacing losses with 5 % dextrose in water [11]. The 
dose of Tolvaptan was not standardized as the decision 
on the dose to be administered was left to the attending 
intensivist. We performed a post hoc subgroup dividing 
patients by the dose they receive (either 7.5 or 15 mg).
Patients who were given Tolvaptan were identified from 
pharmacy records; we then retrieved their paper charts 
and analyzed their clinical course. The data collected 
included age, sex, diagnosis, ICU and hospital length 
of stay, dose and duration of Tolvaptan administration, 
Sequential Organ Failure Assessment (SOFA) score, ICU, 
and in-hospital mortality. Hemodynamic data including 
mean arterial pressure, heart rate, arterial lactate, base 
excess, rates of inotrope, and vasopressor infusions were 
recorded, as was 24-h urine output and the net fluid bal-
ance, the total amount of sodium administered and the 
daily sodium balance, the duration of hyponatremia prior 
to treatment and the day of Tolvaptan administration 
from ICU admission, serum and urine sodium and potas-
sium at initiation of treatment and every 24 h. Additional 
laboratory data included serum creatinine, blood urea 
nitrogen (BUN), liver function tests, albumin, and hemo-
globin concentration. Osmolality in serum and urine 
was not formally measured, and it was calculated using a 
standard formula; only 17 patients had urinary nitrogen 
determinations. We thus decided to present two different 
pieces of information on urinary osmolality: on the one 
hand, we calculated urinary salt osmolality (i.e., twice the 
sum of urinary sodium and potassium), which was avail-
able in all patients; on the other hand, for the subgroup 
of patients in which this was available, we also calculated, 
with a standard formula, total urinary osmolality. Data 
were collected as close as possible to the drug adminis-
tration, and up to 72  h thereafter where this was avail-
able. Adverse events including hypotension and excessive 
rise in sodium concentration were recorded.
Outcomes
The primary outcome was the efficacy of Tolvaptan in 
correcting hyponatremia, defined as the percentage of 
patients with an absolute increase in [Na+] ≥ 4 mmol/L 
over baseline at 24  h after administration of the drug. 
This was selected for consistency with previous reports 
of similar interventions [31–33]. Secondary outcomes 
included absolute increase in [Na+] at 24  h, absolute 
increase of [Na+] at 72 h, and absolute decrease in urine 
sodium concentration. Sodium-free water clearance 
was estimated from an established equation using urine 
volume and urine and serum sodium [34]. As a safety 
endpoint, the rate correction of hyponatremia was exam-
ined. A rapid correction was defined as any increase in 
[Na+]  ≥  12  mmol/L after 24  h [11]. We also searched 
for adverse reactions resulting from hypovolemia and 
increased diuresis such as hemodynamic compromise 
and effects on serum potassium and renal function. An 
exploratory analysis was also conducted, to assess pos-
sible pre-treatment variables that could predict the 
response to therapy.
Statistical analysis
Data are represented as mean values ±  standard devia-
tion if variables are normally distributed (as assessed by 
Shapiro–Francia test), or median (interquartile range) if 
not. Due to the observational nature of the study in a field 
for which no data are available as for the expected effect 
size, we referred to a study in which a vaptan was admin-
istered to a population of non-critically ill patients with 
hyponatremia with preserved total body sodium pool 
[31] to estimate the power. In that study, the percent-
age of patients administered a vaptan vs. placebo who 
increased their [Na+] ≥ 4 mmol/l in 24 h was 58 vs. 11 %. 
Considering a similar effect size and since we enrolled 38 
patients, our study yields a power of 80.4 % with α = 0.05.
Paired Student’s t  test, or the Wilcoxon signed-rank 
test, was used for the comparison of variables between 
baseline and 24  h after Tolvaptan administration. The 
time course of serum sodium over the first 72 h was stud-
ied with Friedman test with post hoc comparison test. 
The association between the absolute increase in [Na+] 
over the first 24 h and possible predictors of the response 
was assessed by means of parametric or non-parametric 
correlation analysis.
Data were collected from the medical charts and stored 
in an electronic data abstraction form, using a Microsoft 
Excel 2010 spreadsheet (Microsoft Corporation, Red-
mond, Wash). Statistical analysis was performed with 
Stata/SE 12.0 (StataCorp, College Station, TX USA) sta-
tistical software. For all comparisons, p < 0.05 was con-
sidered significant.
Results
Demographics and outcome
38 patients received enteral Tolvaptan. Demograph-
ics and clinical characteristics at ICU admission and at 
study enrollment, as well as ICU and hospital outcomes, 
are reported in Table 1. Average [Na+] at ICU admission 
was 135 [131; 138] (range 113–148). Hyponatremia was 
Page 4 of 9Umbrello et al. Ann. Intensive Care  (2016) 6:1 
diagnosed on average on day 5 [2, 12] from ICU admis-
sion; nadir [Na+] was 132 [131; 134]. Tolvaptan was 
administered on day 8 [4, 13].
Tolvaptan dosing, efficacy, and adverse effects
The average dose of Tolvaptan administered was 7.5 [7.5; 
15]  mg enterally: 24 patients (63  %) received 7.5  mg, 
while the remaining 14 (37  %) received 15  mg. Addi-
tional file  1: Tables S1 and S2 summarize the results of 
the subgroup analysis according to the dose of Tolvaptan 
received. We did not find any relevant difference between 
patients receiving 7.5 vs. 15 mg.
Thirty-one (81.6 %) patients met the criterion for suc-
cessful response, defined as an absolute serum sodium 
increase ≥4 mmol/L 24 h after Tolvaptan administration. 
Table  2 shows the primary and secondary outcomes of 
the study.
Before fluid restriction, mean baseline [Na+] was 133 
[131; 134] (range 113–135) mmol/L. After a 24  h trial of 
fluid restriction, it was 133 [132; 135] (range 114–135) 
mmol/L (p = 0.431), and increased to 138 [137; 141] (range 
128–147) mmol/L at 24 h after administration of Tolvaptan 
(p < 0.001). Increase in [Na+] was sustained at 48 and 72 h 
after administration of Tolvaptan (139 [137; 140] (range 
126–147) and 137 [135; 140] (range 133–143)  mmol/L, 
respectively; p < 0.001). Fig 1 shows individual patient time 
course of serum sodium data. Table 3 shows the compari-
son of serum and urine electrolytes, sodium and fluid bal-
ance, hemodynamics, and liver and kidney function tests 
before and 24  h after administration of Tolvaptan. Fig  2 
shows the changes in urine output and sodium-free water 
clearance observed before and 24 h after administration of 
Tolvaptan, as well as the change in serum and urine osmo-
lality. No subsequent doses of Tolvaptan were adminis-
tered. [Na+] at ICU discharge was 139 [136; 140].
Four patients (10.5 %) experienced rapid correction of 
hyponatraemia at 24 h; all patients increased their serum 
sodium of 14  mEq/L. All events were asymptomatic. 
No cases of hypokalemia or hyperkalemia occurred; 1 
patient (2.6  %) developed mild hypernatremia ([Na+] 
147 mEq/L). No other adverse events were documented.
Determinants of serum sodium increase
Serum sodium (R  =  −0.622, p  <  0.001), urine sodium 
(R  =  −0.345, p  <  0.001), central venous blood oxygen 
saturation (R = 0.401, p = 0.013), and BUN (R = −0.416, 
p = 0.031) before Tolvaptan administration were all sig-
nificantly correlated with the absolute increase in [Na+] 
24 h after Tolvaptan administration.
Discussion
Maintenance of plasma osmolality and sodium concen-
trations within tight limits is one of the most highly regu-
lated parameters of body physiology [35]; osmotically 
Table 1 Patient demographics and  clinical data at  enroll-
ment
Age (years) 53 ± 15
Male sex 24 (63.1 %)
Height (cm) 170 ± 9
Body weight (kg) 76 ± 21
Ideal body weight (kg) 63 ± 7
Body mass index (kg/m2) 26 ± 6
Simplified acute physiology score II 26 ± 12
Admission type
 Medical 26 (68.4 %)
 Surgical unscheduled 12 (31.6 %)
Diagnosis
 Pneumonia 12 (31.6 %)
 Urosepsis 6 (15.8 %)
 Peritonitis 5 (13.2 %)
 TUR syndrome 4 (10.5 %)
 Acute pancreatitis 3 (7.9 %)
 Cardiogenic shock 2 (5.3 %)
 Drug abuse 2 (5.3 %)
 Meningitis 2 (5.3 %)
 Osteomyelitis 1 (2.6 %)
 Chest trauma 1 (2.6 %)
 SOFA score at enrollment 3 [1; 5]
Organ support at enrollment
 Mechanical ventilation 38 (100 %)
 Vasoactive therapy 2 (5.3 %)
 Worst SOFA score during ICU stay 6 (3; 8)
 Length of ICU stay (days) 14 (6; 23)
 ICU mortality 7 (18 %)
 Hospital mortality 12 (31 %)
 Age (years) 53 ± 15
 Male (sex) 24 (63.1 %)
 Height (cm) 170 ± 9
Table 2 Primary and secondary outcomes
Primary outcome
 ≥4 mmol/l increase in serum sodium over baseline at 
24 h—n (%)
31/38 (81.6 %)
Secondary outcomes
 Absolute increase in serum sodium over baseline at 
24 h—mmol/l
6.7 ± 3.4
 Absolute increase in serum sodium over baseline at 
72 h—mmol/l
5.5 ± 3.7
 Absolute reduction in urine sodium over baseline at 
24 h—mmol/l
-68.0 ± 39.9
 ≥12 mmol/l increase in serum sodium over baseline at 
24 h—n (%)
4/38 (10.5 %)
 Average hourly increase in serum sodium—mmol/l*h 0.28 ± 0.14
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induced variations in cell volume can exert adverse 
effects on multiple cellular functions [36]. In virtually 
every disease state, the presence of hyponatremia was 
found to be an independent risk factor for increased 
mortality [11]. Indeed, a recent study in a large number 
of hospitalized hyponatremic patients proposed revising 
the definition of hyponatremia to [Na+]  <  138  mmol/L, 
because this was the level at which the association with 
increased mortality reached statistical significance [37].
Treating hyponatremia thus seems an important step 
in the management of patients, especially for the most 
critically ill. However, this entails choosing among sev-
eral suboptimal therapies, i.e., fluid restriction, salt tab-
lets, slow infusions of 3  % saline, furosemide, and urea 
[6]. In cases of hyponatremia with preserved sodium 
pool, fluid restriction represents the cheapest, first-line 
treatment, despite the almost complete lack of a support-
ive evidence base [11]. The other associated therapeutic 
options, however, are represented by drugs with limited 
efficacy or a doubtful physiologic rationale, in that they 
mainly act on body sodium pool, while it is the water 
pool that is primarily altered. The recent development of 
Fig. 1 Individual patient time course of serum sodium data before 
and up to 72 h after Tolvaptan
Table 3 Changes in electrolytes, hemodynamic, and biochemistry parameters before and after administration of Tolvap-
tan
Before After P
Serum sodium concentration (mmol/l) 133 [132; 135] 138 [137; 141] <0.001
Urine sodium concentration (mmol/l) 123.2 ± 36.5 54.9 ± 5.4 <0.001
Serum potassium concentration (mmol/l) 4.1 ± 0.4 4.2 ± 0.3 0.823
Urine potassium concentration (mmol/l) 32.2 ± 16.8 24.8 ± 15.1 0.015
Urine output (ml/24 h) 2149 ± 966 3593 ± 1673 <0.001
Sodium input (mmol/24 h) 159 [111; 214] 148 [115; 169] 0.824
Sodium balance (mmol/24 h) −69 [143; 20] −49 [−146; 37] 0.789
Sodium output (mmol/24 h) 236.5 [120; 311] 190.5 [119.5; 298.5] 0.654
Sodium-free water clearance (%) 9.6 [−12.0; 24.4] 59.9 [43.3; 76.6] <0.001
Fluid balance (ml/24 h) −200 [−950; 0] −1300 [−2200; −550] <0.001
Heart rate (1/min) 90.3 ± 18.2 92.1 ± 20.4 0.467
Mean arterial pressure (mmHg) 84.3 ± 13.9 82.7 ± 11.0 0.413
Central venous pressure (mmHg) 7.1 ± 3.6 6.1 ± 4.1 0.089
Patients on vasopressors 1/38 1/38 >0.999
Central venous oxygen saturation (%) 71.6 ± 7.4 70.9 ± 7.2 0.445
Albumin concentration (g/100 ml) 2.3 ± 0.3 2.6 ± 0.3 0.015
Hemoglobin concentration (g/100 ml) 10.6 ± 2.0 10.8 ± 2.0 0.098
Aspartate aminotransferase (IU/l) 59 ± 27 49 ± 22 0.114
Alanine aminotransferase (IU/l) 84 ± 55 80 ± 56 0.439
Bilirubin concentration (mg/100 ml) 1.8 ± 1.3 1.9 ± 1 0.986
Serum creatinine concentration (mg/100 ml) 0.9 ± 0.6 0.8 ± 0.5 0.053
Blood urea nitrogen (mg/100 ml) 23.6 ± 13.3 20.1 ± 11.5 0.015
Serum lactate concentration (mmol/l) 1.2 ± 0.7 1.0 ± 0.4 0.261
Serum glucose concentration (mg/100 ml) 126 ± 28 120 ± 21 0.194
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the new pharmacologic approach of aquaresis— i.e., elec-
trolyte-free water excretion— allows for removal of water 
not accompanied by elimination of sodium and other 
electrolytes [38].
Tolvaptan is an oral, competitive, selective vasopres-
sin V2-receptor antagonist. It was shown to be effective 
in reversing hyponatremia with preserved total body 
sodium pool ([Na+]  <  135  mmol/L) in the SALT-1 and 
SALT-2 trials [24]. Pooled results for all patients showed 
changes in average daily serum sodium of 4.0 mmol/L vs 
0.4 mmol/L for placebo at day 4. A post hoc analysis of 
the phase III EVEREST trial demonstrated that patients 
hospitalized for heart failure with baseline hyponatremia 
who received Tolvaptan had an adjusted mean length of 
stay shorter compared with that for patients receiving 
placebo [25]. Tolvaptan was also shown to reduce hospi-
tal length of stay vs. placebo among patients with SIAD in 
the SALT-1 and -2 trials [39]. A recent meta-analysis on 
11 trials (1094 patients) showed how the use of vaptans 
resulted in a 24-h net increase in [Na+] of 3.3  mmol/L 
relative to the control group [17].
However, the published experience in current clinical 
practice and in patients not enrolled in randomized trials 
remains limited, particularly in the field of critical care 
medicine. Furthermore, clinical factors which can predict 
the extent of the response are not completely defined. 
The present investigation is one of the very few report-
ing experience of vaptans in critically ill patients, previ-
ous studies being case reports, or open label randomized 
studies assessing interest of Conivaptan in neuro-ICU 
patients with [40] or without [41] hyponatremia.
In this case series, we present a mixed cohort of criti-
cally ill patients who were either admitted to the ICU 
or developed during their stay a moderate hypotonic 
hyponatremia. The patients had no history of reduction 
in their total sodium pool, nor did they present any sign 
or symptom of overt hypovolemia (as evaluated by their 
values of hemodynamic parameters, urine output, blood 
lactate, ScvO2, skin perfusion); urine sodium was above 
the normal range. However, the average concentration 
of 10 g/100 ml hemoglobin associated with 23 g/l albu-
min (Table 2), widely tolerated combination of hypoalbu-
minemia/anemia frequently seen in critically ill patients 
[42], might have contributed to the activation of AVP 
(given the altered circulating blood volume), besides the 
well-known factors (acute respiratory failure, pneumo-
nia, trauma, mechanical ventilation, history of COPD) [8] 
that are nonetheless present in the case-mix.
After a trial of fluid restriction, Tolvaptan was admin-
istered enterally (via nasogastric tube) and, given the 
lack of previous experience with this drug in critically ill 
patients, we decided to use lower doses than generally 
used (on average, 7.5 mg). Even so, we report a rapid and 
effective response (average increase of 7 mmol/l in 24 h) 
that nonetheless lasted up to 72 h after the first admin-
istration, again underscoring the feasibility of the enteral 
route for critically ill patients [43, 44]. Tolvaptan signifi-
cantly increased [Na+] and reduced urine sodium, with 
no changes in either plasma or urine potassium. Moreo-
ver, sodium input and sodium balance were unchanged 
from before and after administration of the drug; still, 
urine output increased about 1.5  l, indicating free water 
diuresis (Fig.  2). The increased diuresis and the conse-
quent negative fluid balance were not associated with any 
hemodynamic modification, nor did they induce hypop-
erfusion, again indicating the previously increased total 
body water pool and a likely osmotically driven reduction 
in the increased cell water content after administration 
of Tolvaptan. The decrease in urine [Na+] concentration 
was likely a dilutional effect of the increased urine water 
content, as total urine sodium output did not change 
significantly.
Fig. 2 Changes in urine output and sodium-free water clearance 
(upper panel) and in serum and urine osmolality (lower panel) before 
and 24 h after Tolvaptan. Urine osmolality was calculated either as 
salt osmolality (i.e., the part of osmolality exerted by strong ions) and, 
for the subset of patients in whom urinary nitrogen determinations 
were available, as total urinary osmolality. *p < 0.01 before vs. after 
Tolvaptan
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Only about 10  % of patients experienced a daily 
increase in plasma sodium  >12  mmol/l. Since overly 
rapid correction of hyponatremia risks iatrogenic brain 
damage, a 1-day increase of 12  mmol/L/d is generally 
considered a safe threshold [11]. However, the risk of 
central pontine myelinolysis varies depending on several 
factors, and it is unlikely to occur if serum Na concen-
tration is  >120  mEq/L [11]. One patient became mildly 
hypernatremic (147  mEq/L), and despite the fact that 
he developed no neurological symptoms, this should be 
acknowledged as development of hypernatremia is a risk 
factor for osmotic demyelination [11]. Indeed, none of 
these patients reported abnormalities to the neurologic 
examination, and particularly no cases of central pon-
tine myelinolysis or any other severe neurological dam-
age were seen. Moreover, this rate of correction is in line 
with other data on hyponatremia with preserved sodium 
pool in larger group of patients studied in the Hypona-
tremia Registry [5], or in patients treated with Tolvaptan 
[17], and lower than reported with the use of intrave-
nous Conivaptan [33], thus suggesting a low prevalence 
of such side-effect with the low doses we used or a less 
drastic effect of enteral administration of the drug. We 
did not report any other relevant side-effect, and specifi-
cally, we did not see any short-term alteration in liver or 
kidney function tests.
We observed a certain degree of variability in the 
response to Tolvaptan administration. To better eluci-
date the potential mechanisms, and to possibly provide 
clinicians with predictors of the response to Tolvaptan, 
we searched for variables associated to the degree of the 
effect. As already reported [23, 33, 45], baseline [Na+] 
was negatively associated with the subsequent rise in 
[Na+] resulting from treatment, i.e., the lower the base-
line [Na+], the bigger the response. This could merely 
reflect the fact that subjects with higher baseline [Na+] 
have less room for improvement, and likely reflect a 
lower degree of AVP activation. Furthermore, our study 
shows how baseline urine sodium has a negative associa-
tion with [Na+] rise. This likely depends from a higher 
AVP activation leading to an elevated urine sodium, that 
might have necessitated higher doses of Tolvaptan for the 
same effect to take place, and is in line with the competi-
tive nature of the AVP antagonism exerted by the drug. 
The positive correlation with ScvO2 might mean that 
patients with a relatively more increased body water pool 
tend to have a bigger response. Eventually, the negative 
correlation with BUN, as already seen with intravenous 
Conivaptan [33], likely depends on the fact that hypou-
raemia is a known feature of SIAD [46] (decreased proxi-
mal tubular reabsorption of urea and increased GFR 
resulting from expansion of body water pool [47]). One 
could speculate that subjects with the lowest BUN levels 
carry the largest increase in whole body water content, 
greatest extracellular fluid expansion, highest GFR, low-
est proximal tubular reabsorption, and greatest distal 
delivery of substrate, thereby making them more respon-
sive to water diuresis.
Study limitations
Potential limitations of the present study include the 
small sample population in a heterogeneous population 
of critically ill patients and the lack of statistical power 
in detecting significant side effects or complications of 
unwarranted fast corrections of hyponatremia. However, 
we succeeded in testing our primary hypothesis, which 
showed a significant improvement in [Na+] without 
short-term negative effects in a real-life scenario. Sec-
ondly, as a single-center study with no control group for 
comparison, the generalizability of the present results is 
limited. Moreover, given the observational nature of the 
study, the statistical associations between serum sodium 
concentration and outcome cannot be considered as 
causal relationship. Furthermore, factors correlated with 
sodium increase following Tolvaptan administration 
were evaluated using bivariate correlation; however, the 
reported factors might be either predictors of confound-
ing factors not taken into account because of the limited 
sample size, which precluded any such correction. Larger 
prospective, placebo-controlled, randomized studies are 
needed to confirm the effects of Tolvaptan treatment as 
well as its cost-effectiveness. Finally, the long-term effects 
of low-dose Tolvaptan in this population were not tested 
in the present study.
Conclusions
In conclusion, this is the first case series to suggest that 
enteral administration of oral Tolvaptan is an effective 
aquaretic for the treatment of hyponatremia with pre-
served total body sodium pool in a heterogeneous cohort 
of critically ill patients. Further prospective well-designed 
studies are required to determine if the administration 
of Tolvaptan to critically ill hyponatremic patients can 
improve their clinical outcome.
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